EydisBio Receives FDA Orphan Drug Designation for TAK1 Inhibitor for the Treatment of Systemic Sclerosis

EydisBio is a start-up founded by Professor Timothy Haystead (P&CB, SOM) focusing on the treatment of autoimmune and inflammatory diseases.